维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Santo Colosimo"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Bile acids as drivers and biomarkers of hepatocellular carcinoma显示文摘The prevalence of hepatocellular carcinoma(HCC)is rapidly increasing,driven not least in part by the escalating prevalence of non-alcoholic fatty liver disease.Bile acid(BA)profiles are altered in patients with HCC and there is a developing body of evidence from in vitro human cellular models as well as rodent data suggesting that BA are able to modulate fundamental processes that impact on cellular phenotype predisposing to the development of HCC including senescence,proliferation and epithelial-mesenchymal transition.Changes in BA profiles associated with HCC have the potential to be exploited clinically.Whilst excellent diagnostic and imaging tools are available,their use to screen populations with advanced liver disease at risk of HCC is limited by high cost and low availability.The mainstay for HCC screening among subjects with cirrhosis remains frequent interval ultrasound scanning.Importantly,currently available serum biomarkers add little to diagnostic accuracy.Here,we review the current literature on the use of BA measurements as predictors of HCC incidence in addition to their use as a potential screening method for the early detection of HCC.Whilst these approaches do show early promise,there are limitations including the relatively small cohort sizes,the lack of a standardized approach to BA measurement,and the use of inappropriate control comparator samples.	Santo Colosimo Jeremy W Tomlinson	2022	World Journal of Hepatology2022，14，9：	2

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费